Detalhe da pesquisa
1.
Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1/3 reduction in T-cells.
Am J Physiol Gastrointest Liver Physiol
; 320(3): G396-G410, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355506
2.
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).
AIDS Res Hum Retroviruses
; 38(4): 269-278, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34384282
3.
Evaluation of the Safety, Acceptability, and Pharmacokinetic Profile of a Gel Formulation of OB-002 in Healthy Volunteers.
AIDS Res Hum Retroviruses
; 37(6): 453-460, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33749321
4.
The Use of Droplet Digital PCR to Quantify HIV-1 Replication in the Colorectal Explant Model.
AIDS Res Hum Retroviruses
; 35(3): 326-334, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30618283
5.
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV.
AIDS Res Hum Retroviruses
; 35(9): 794-804, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31146534
6.
Immunological responsiveness of intestinal tissue explants and mucosal mononuclear cells to ex vivo stimulation.
J Immunol Methods
; 463: 39-46, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30218652
7.
Ranpirnase Reduces HIV-1 Infection and Associated Inflammatory Changes in a Human Colorectal Explant Model.
AIDS Res Hum Retroviruses
; 34(10): 838-848, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29936861
8.
Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.
PLoS One
; 11(6): e0158310, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27362788
9.
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
Lancet HIV
; 3(12): e569-e578, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27658864
10.
A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
PLoS One
; 10(5): e0125363, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25942472